Investor Overview

Overview
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART (Safely Metabolized And Rationally Targeted) linker drug discovery platform enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART linker platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates.
Recent News
09.28.16
Catabasis Pharmaceuticals Announces Closing of $11.5 Million Offering of Common Stock, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
09.23.16
Catabasis Pharmaceuticals Announces Pricing of $10 Million Offering of Common Stock
08.11.16
Catabasis Pharmaceuticals Reports Second Quarter 2016 Financial Results and Recent Corporate Highlights
IR Contact
Andrea Matthews
Phone: (617) 349-1971
E-mail: amatthews@catabasis.com

Upcoming Events
There are currently no events scheduled.
The documents contained in (or directly accessible from) this website include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions. There are a number of important factors that could cause Catabasis’ actual results to differ materially from those indicated by such forward-looking statements, including factors identified in the company’s most recent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was first made.